RavenQuest Receives Health Canada Permit for Export to Australia
08 Outubro 2019 - 7:00AM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”), one of Canada’s most innovative
cannabis producers, announces that it has received a permit from
Health Canada to allow the Company to export cannabis to Australia.
The permit allows for the export of dried
cannabis flower from the Company to Medcan Australia
(“Medcan”), a federally licensed Australian
medical cannabis provider. Shipments from RavenQuest to
Medcan are targeted to begin in mid-October.
Founded in 2016, Medcan has a singular vision to
provide Australian patients with a high-quality, fair-priced
product. With a vertically integrated model, Medcan is
licenced under the Office Drug Control to cultivate, produce,
manufacture, export and import high quality medicinal cannabis
products for both clinical trials and individual patient access
throughout Australia.
RavenQuest CEO, George Robinson, stated “the
Australian medical cannabis model is well developed and mirrors
Canada’s early evolution in many respects. With a population of
over 24 million residents, this is a significant market with real
growth potential. The Special Access Scheme in Australia has
been updated recently, making it easier to access medical cannabis.
Of the 14,420 applications approved, 13,217, or 92%, occurred
within the last 12 months, and 2,893, or 20%, in August 2019
alone. It’s clear to us that the Australian medical cannabis
market is growing very rapidly and we can now participate in this
growth through our export permit with Health Canada.”
Medcan CEO, Craig Cochran, commented “we are
very excited to begin receiving cannabis from Canada’s
RavenQuest. After a comprehensive facility tour through
RavenQuest’s ultra-modern, laboratory-grade cultivation facilities,
we are confident their product easily meets our high cleanliness
and safety standards. We also had in depth discussions with
RavenQuest’s plant science leader, Dr. Simerjeet Kaur and are very
comfortable with the RavenQuest team’s ability to continue our
commitment to provide the safest and highest quality cannabis to
our patients.”
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
Follow
RavenQuest:TwitterInstagramFacebookLinkedIn
About RavenQuest BioMed
Inc.
RavenQuest is a diversified publicly traded
cannabis company with divisions focused upon cannabis production,
management services & consulting and specialized research &
development. RavenQuest is a licensed producer with facilities
located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant.
The Company focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications1-877-282-1586
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statement
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws. Examples of such statements include statements
with respect to the export of cannabis from RavenQuest to Medcan.
The Company provides forward-looking statements for the purpose of
conveying information about current expectations and plans relating
to the future and readers are cautioned that such statements may
not be appropriate for other purposes. By its nature, this
information is subject to inherent risks and uncertainties that may
be general or specific and which give rise to the possibility that
expectations, forecasts, predictions, projections or conclusions
will not prove to be accurate, that assumptions may not be correct
and that objectives, strategic goals and priorities will not be
achieved. These risks and uncertainties include but are not limited
those identified and reported in the Company’s public filings under
the Company’s SEDAR profile at www.sedar.com. Although the Company
has attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking information, there may be other
factors that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. The Company disclaims any intention or obligation
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise unless
required by law.
RavenQuest BioMed (CSE:RQB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
RavenQuest BioMed (CSE:RQB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024